GKOS (Glaukos) Cyclically Adjusted FCF per Share: $-0.59 (As of Mar. 2026)


GKOS Glaukos Corp GKOS
79 GF Score
Price $142.69
GF Value $135.47
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos Cyclically Adjusted FCF per Share?

Glaukos GKOS -1.20% 79 Cyclically Adjusted FCF per Share is $-0.59 as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 79/100 and a GF Value™ of $135.47 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Glaukos's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.284. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.59 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-06-29), Glaukos's current stock price is $142.69. Glaukos's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.59. Glaukos's Cyclically Adjusted Price-to-FCF of today is .


Glaukos  (NYSE:GKOS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Glaukos Cyclically Adjusted FCF per Share Related Terms


Glaukos Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Glaukos's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Cyclically Adjusted FCF per Share Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.39 -0.49 -0.56

Glaukos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.52 -0.54 -0.56 -0.59

GKOS vs BIO, BRKR, PODD: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Glaukos's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Glaukos's Cyclically Adjusted Price-to-FCF falls into.


GKOS
79GF Score
Glaukos Corp GKOS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glaukos's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.284/330.2130*330.2130
=-0.284

Current CPI (Mar. 2026) = 330.2130.

Glaukos Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.144 241.018 0.197
201609 0.025 241.428 0.034
201612 0.033 241.432 0.045
201703 0.041 243.801 0.056
201706 0.087 244.955 0.117
201709 0.122 246.819 0.163
201712 0.307 246.524 0.411
201803 -0.222 249.554 -0.294
201806 0.088 251.989 0.115
201809 0.102 252.439 0.133
201812 0.265 251.233 0.348
201903 -0.012 254.202 -0.016
201906 0.130 256.143 0.168
201909 -0.108 256.759 -0.139
201912 -0.098 256.974 -0.126
202003 -0.317 258.115 -0.406
202006 -0.308 257.797 -0.395
202009 -0.243 260.280 -0.308
202012 0.188 260.474 0.238
202103 -0.284 264.877 -0.354
202106 -0.086 271.696 -0.105
202109 0.160 274.310 0.193
202112 -0.298 278.802 -0.353
202203 0.064 287.504 0.074
202206 -0.456 296.311 -0.508
202209 -0.684 296.808 -0.761
202212 -0.259 296.797 -0.288
202303 -0.787 301.836 -0.861
202306 -0.288 305.109 -0.312
202309 -0.237 307.789 -0.254
202312 -0.304 306.746 -0.327
202403 -0.703 312.332 -0.743
202406 -0.405 314.175 -0.426
202409 -0.201 315.301 -0.211
202412 -0.022 315.605 -0.023
202503 -0.361 319.799 -0.373
202506 0.101 322.561 0.103
202509 -0.204 324.800 -0.207
202512 -0.220 324.054 -0.224
202603 -0.284 330.213 -0.284

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.59 mean?
Glaukos (GKOS) has a Cyclically Adjusted FCF per Share of $-0.59 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Glaukos and its competitors.
Is Glaukos' Cyclically Adjusted FCF per Share too high?
Glaukos' current Cyclically Adjusted FCF per Share is $-0.59. Overall, Glaukos has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Cyclically Adjusted FCF per Share compare to BIO and BRKR?
Glaukos' Cyclically Adjusted FCF per Share of $-0.59 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Glaukos and its competitors. Glaukos's current Cyclically Adjusted FCF per Share is $-0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.47, compared to a current price of $142.69 — trading 5.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.59. Glaukos' overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Glaukos (GKOS), the current Cyclically Adjusted FCF per Share is $-0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $142.69 is trading 5.3% above its estimated GF Value™ of $135.47. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for GKOS:

  • Cyclically Adjusted FCF per Share: $-0.59
  • GF Value™: $135.47 vs. price of $142.69 (5.3% above fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
79GF Score

Get the complete analysis for GKOS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$142.69
Price
$135.47
GF Value